University of Kansas Medical Center
kumc.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
487
Active
139
Phase 3
12
Total enrollment
67,918
Pipeline matrix
Showing 40 of 51 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Tranexamic Acid | — | — | — | — | 3 | ||
| Thrombin JMI | — | — | — | — | — | 1 | |
| triamcinolone acetonide extended-release injectable suspension; TCA-ER | — | — | — | — | — | 1 | |
| Triamcinolone Acetonide- Immediate Release;TCA-IR | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | 3 | ||
| Nivolumab | — | — | — | — | 3 | ||
| Bupropion | — | — | — | — | — | 3 | |
| Varenicline Tartrate | — | — | — | — | — | 2 | |
| Sirolimus | — | — | — | — | — | 1 | |
| ascorbic acid | — | — | — | 3 | |||
| Docetaxel | — | — | — | — | — | 5 | |
| Cyclophosphamide | — | — | — | — | 4 | ||
| Carboplatin | — | — | — | — | — | 3 | |
| Saline | — | — | — | — | 3 | ||
| Sacituzumab govitecan | — | — | — | — | 2 | ||
| Losartan | — | — | — | 3 | |||
| Trastuzumab | — | — | — | — | — | 2 | |
| Atezolizumab | — | — | — | — | 2 | ||
| Doxorubicin | — | — | — | — | — | 2 | |
| Bazedoxifene and Conjugated Estrogens | — | — | — | — | — | 1 | |
| CaHMB | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Regorafenib | — | — | — | — | — | 1 | |
| Pertuzumab | — | — | — | — | — | 1 | |
| Relugolix | — | — | — | — | — | 1 | |
| Enfortumab vedotin | — | — | — | — | — | 1 | |
| Intravenous ascorbic acid/vitamin C | — | — | — | — | — | 1 | |
| Metformin Hydrochloride | — | — | — | — | — | 1 | |
| Ascorbic acid solution | — | — | — | — | — | 1 | |
| Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab | — | — | — | — | — | 1 | |
| Adjuvant Treatment - mFOLFOX & Pembrolizumab | — | — | — | — | — | 1 | |
| Onvansertib | — | — | — | — | — | 1 | |
| NALIRIFOX | — | — | — | — | — | 1 | |
| TG01 Vaccine | — | — | — | — | — | 1 | |
| QS-21 | — | — | — | — | — | 1 | |
| Balstilimab | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | — | 2 | ||
| Hydrochlorothiazide 12.5Mg Tab | — | — | — | — | — | 1 | |
| Clonidine Pill | — | — | — | — | — | 1 | |
| DuoCAR20.19.22-D95 | — | — | — | — | — | 1 |
11 more active programs hidden
Next readouts
- 2022-09-12
- 2024-02-23
- 2024-04-30
- 2024-12
- 2025-01-28
- 2025-06-01
- 2025-10-23
- 2025-11-12
- 2026-03-01
- 2026-07
Top conditions
- Breast Cancer22
- Obesity17
- Bladder Cancer14
- Smoking Cessation12
- Alzheimer Disease12
- Dementia11
- Prostate Cancer9
- Hypertension8
Frequently asked questions about University of Kansas Medical Center
- How many clinical trials does University of Kansas Medical Center have on ClinicalTrials.gov?
- University of Kansas Medical Center is listed as the lead sponsor on 487 clinical trials in ClinicalTrials.gov, 139 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Kansas Medical Center's trials are in Phase 3?
- 12 of University of Kansas Medical Center's trials are in Phase 3, spread across 51 active drug programs.
- What therapeutic areas does University of Kansas Medical Center focus on?
- University of Kansas Medical Center's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Obesity, Bladder Cancer, Smoking Cessation, Alzheimer Disease.
- When are University of Kansas Medical Center's next clinical trial readouts?
- University of Kansas Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients”, expected around 2022-09-12.